<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="703">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855738</url>
  </required_header>
  <id_info>
    <org_study_id>A0081144</org_study_id>
    <secondary_id>LICEO STUDY</secondary_id>
    <nct_id>NCT00855738</nct_id>
  </id_info>
  <brief_title>A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice</brief_title>
  <official_title>Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Spain: Consejeria de Sanidad y Consumo de la Comunidad de Madrid and AEMyPS</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the efficacy under daily clinical conditions of the new antiepileptic drugs
      (AEDs) gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine and
      topiramate, used as first-choice combination therapy (bitherapy) in patients with focal
      epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent of Participants Classified as Responders</measure>
    <time_frame>Baseline, Month 3, Month 6 (last 3 months of treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Responder = decrease in number of seizures by &gt;=50 percent (%) during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the number of seizures that occurred during the 3 months before the baseline visit (baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Reduction in Number of Seizures &gt;=25% and &gt;=75% During the Last 3 Months of Treatment</measure>
    <time_frame>Baseline, Month 3, Month 6 (last 3 months of treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of participants with reduction in number of seizures &gt;=25% and &gt;=75% during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the 3 month period before the baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Seizure-free Participants During the Last 3 Months Before Discontinuation</measure>
    <time_frame>Baseline, Month 3, Month 6 (last 3 months of treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Median Number of Seizures During the Last 3 Months of Treatment</measure>
    <time_frame>Baseline, Month 3, Month 6 (last 3 months of treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Days Without Crisis During the Study</measure>
    <time_frame>Baseline through Month 6 (or end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Crisis was defined as the total number of seizures during the study, the seizures at month 3 plus the seizures at month 6. The percent of days without crisis is number of days of study (date of last visit minus date of baseline visit) without crisis divided by number of days of study, multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Seizure</measure>
    <time_frame>Baseline to Month 6 (or end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of days to first seizure after baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Who Continued on Study Medication to Month 6</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Retention rate: percent of participants who continued on study medication throughout the 6 Month period after inclusion in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation Due to Lack of Efficacy</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation Due to Safety, Tolerability, or Treatment Compliance</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation Due to Other Reasons</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Evaluated by Patient Global Impression of Change Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient Global Impression of Change VAS: subject rated instrument to measure subject's change in overall status; range from 0 (much better) to 10 (much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Reaching Monotherapy</measure>
    <time_frame>Baseline through Month 6 (or end of study)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of participants who started on more than one treatment (bitherapy) and reached monotherapy by end of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants That Reduced, Maintained and Increased Their Doses of New Antiepileptic Drugs (AED)</measure>
    <time_frame>Baseline to Month 6 (or end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants That Reduced, Maintained and Increased the Doses of the Initial Treatment Administered in Monotherapy</measure>
    <time_frame>Baseline through Month 6 (or end of treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in the Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>HADS: subject rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in Quality of Life 10 Domains (QOLIE-10)</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>QOLIE-10: 10-item questionnaire evaluates health-related quality of life in individuals with epliepsy. Comprised of 7 components: seizure worry, overall quality of life, emotional well-being, energy, cognitive functioning, medication effects (physical and mental effects), and social function (work, driving, social function). Total score rated 0 to 100; higher score = higher quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Months 3 and 6 in Health Condition: Euro Quality of Life Scale (EQ-5D) Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, Month 3, Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of the health condition of the subjects using the EQ-5D VAS: subject rated questionnaire to assess health-related quality of life in terms of a single index value. Using the VAS subjects rated current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Disturbances From Baseline to Month 6: Medical Outcomes Study Sleep Scale (MOS-SS)</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject rated instrument to assess key constructs of sleep; assesses sleep quality and quantity. Consists of a 6-item and 9-item overall sleep problems index measuring time to fall asleep and sleep duration in past 4 weeks; 5 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy. Transformed scores range = 0 to 100; higher score indicates greater intensity of attribute. Two additional subscales = sleep quantity (range 0-24 hours) and optimal sleep (number of participants with optimal sleep 7-8 hours per night).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Indicating Optimal Sleep on the Optimal Sleep Subscale: Medical Outcomes Study Sleep Scale (MOS-SS)</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>MOS-SS: subject rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Optimal sleep subscale is derived from sleep quantity average hours of sleep over the past 4 weeks; percent of participants with response YES (optimal) if sleep quantilty was 7-8 hours of sleep per night.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in Visits to a Specialist or the Emergency Room Because of Epilepsy</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Numerical assessment of change in the number of visits to a specialist or the emergency room because of epilepsy needed during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 6 in Total Number of Days Hospitalized Because of Epilepsy</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Numerical assessment of change in total number of days hospitalized because of epilepsy during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Cessation of Occupation, Requirement of Caregiver, or Admission to Intensive Care Unit</measure>
    <time_frame>Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of participants with cessation of usual occupation, requirement of an informal caregiver, and who required admission to the intensive care unit (ICU).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Focal Epilepsy</condition>
  <arm_group>
    <arm_group_label>1.0</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide</intervention_name>
    <description>Gabapentin: up to 3.600 mg/d
Lamotrigine: up to 400 mg/d
Levetiracetam: up to 3.000 mg/d
Pregabalin: up to 600 mg/d
Oxcarbazepine: up to 2.400 mg/d
Tiagabine: up to 30 mg/d
Topiramate: up to 400 mg/d
Zonisamide: up to 500 mg/d</description>
    <arm_group_label>1.0</arm_group_label>
    <other_name>Neurontin, Lamictal, Lyrica, Keppra, Topamax, Gabatril, Episen, Zonegran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older.

          -  Diagnosis of focal epilepsy.

          -  Previous failure of one or more AEDs used in monotherapy.

          -  Background treatment with an antiepileptic drug.

          -  The investigator has considered that the patient must start treatment with some of
             the seven new AEDs in combination therapy: lamotrigine, levetiracetam, gabapentin,
             oxcarbazepine, pregabalin, tiagabine and/or topiramate.

          -  History of seizures in the patient in the past 3 months.

          -  The patient or legal guardian must be able to understand the characteristics of the
             study and fill in the seizure diaries.

          -  Written informed consent.

        Exclusion Criteria:

          -  Inability to comply with the study requirements.

          -  Diagnosis of generalized epilepsy or inability to establish if focal or generalized.

          -  Presence of serious or uncontrolled systemic disease, serious psychiatric disease or
             progressive neurological disease.

          -  History of alcoholism, drug addiction, or abuse of medicines in the past two years.

          -  Psychogenic seizures in the two years prior to inclusion in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081144&amp;StudyName=A%20Prospective%2C%20Observational%20Study%20On%20The%20Effectiveness%20Of%20New%20Antiepileptic%20Drugs%20As%20First%20Bitherapy%20In%20The%20Daily%20Clinical%20Practice</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2010</verification_date>
  <lastchanged_date>November 23, 2010</lastchanged_date>
  <firstreceived_date>March 3, 2009</firstreceived_date>
  <firstreceived_results_date>June 23, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>epilepsy antiepileptic biotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticonvulsants</mesh_term>
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Tiagabine</mesh_term>
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Given the observational nature of the study, the selection of treatment and dose of study medication was independent from participation in the study and was determined by daily clinical practice.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Antiepileptic Drugs</title>
          <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>At Least 1 Dose and 1 Endpoint</title>
              <participants_list>
                <participants group_id="P1" count="108">Received at least 1 dose of study drug and had data for at least 1 efficacy endpoint.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Defaulted</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Antiepileptic Drugs</title>
          <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="111"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.3" spread="16.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="52"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="59"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Classified as Responders</title>
        <description>Responder = decrease in number of seizures by &gt;=50 percent (%) during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the number of seizures that occurred during the 3 months before the baseline visit (baseline).</description>
        <time_frame>Baseline, Month 3, Month 6 (last 3 months of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set (FAS): intent-to-treat population = those who took at least 1 dose of study medication and had post-baseline data for at least 1 efficacy endpoint. Last Observation Carried Forward (LOCF) captures last 3 months of treatment for subjects who discontinued between Month 3 and Month 6 only. N=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants Classified as Responders</title>
            <description>Responder = decrease in number of seizures by &gt;=50 percent (%) during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the number of seizures that occurred during the 3 months before the baseline visit (baseline).</description>
            <units>percent of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Month 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.7" lower_limit="66.6" upper_limit="84.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80.0" lower_limit="70.2" upper_limit="87.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 3: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 6: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Reduction in Number of Seizures &gt;=25% and &gt;=75% During the Last 3 Months of Treatment</title>
        <description>Percent of participants with reduction in number of seizures &gt;=25% and &gt;=75% during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the 3 month period before the baseline visit.</description>
        <time_frame>Baseline, Month 3, Month 6 (last 3 months of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. N=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants With Reduction in Number of Seizures &gt;=25% and &gt;=75% During the Last 3 Months of Treatment</title>
            <description>Percent of participants with reduction in number of seizures &gt;=25% and &gt;=75% during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the 3 month period before the baseline visit.</description>
            <units>percent of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Month 3: &gt;=25%</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86.7" lower_limit="77.9" upper_limit="92.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3: &gt;=75%</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.8" lower_limit="18.8" upper_limit="38.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6: &gt;= 25%</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86.7" lower_limit="77.9" upper_limit="92.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6: &gt;=75%</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54.4" lower_limit="43.6" upper_limit="65.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 3 &gt;=25% reduction: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 3 &gt;=75% reduction: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 6: &gt;=25% reduction: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 6: &gt;=75% reduction: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Seizure-free Participants During the Last 3 Months Before Discontinuation</title>
        <time_frame>Baseline, Month 3, Month 6 (last 3 months of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. N=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Seizure-free Participants During the Last 3 Months Before Discontinuation</title>
            <units>percent of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Month 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10.0" lower_limit="4.7" upper_limit="18.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.0" lower_limit="12.3" upper_limit="29.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 3: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0039</p_value>
            <method>McNemar</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 6: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Median Number of Seizures During the Last 3 Months of Treatment</title>
        <time_frame>Baseline, Month 3, Month 6 (last 3 months of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS LOCF. N=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in the Median Number of Seizures During the Last 3 Months of Treatment</title>
            <units>percent change</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-75.0" lower_limit="-88.9" upper_limit="-50.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Days Without Crisis During the Study</title>
        <description>Crisis was defined as the total number of seizures during the study, the seizures at month 3 plus the seizures at month 6. The percent of days without crisis is number of days of study (date of last visit minus date of baseline visit) without crisis divided by number of days of study, multiplied by 100.</description>
        <time_frame>Baseline through Month 6 (or end of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The percentage of days without crisis during the study was not evaluable because a diary with the daily number of crises was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Days Without Crisis During the Study</title>
            <description>Crisis was defined as the total number of seizures during the study, the seizures at month 3 plus the seizures at month 6. The percent of days without crisis is number of days of study (date of last visit minus date of baseline visit) without crisis divided by number of days of study, multiplied by 100.</description>
            <units>percentage of days</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Seizure</title>
        <description>Number of days to first seizure after baseline.</description>
        <time_frame>Baseline to Month 6 (or end of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS LOCF. N=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to First Seizure</title>
            <description>Number of days to first seizure after baseline.</description>
            <units>days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="35.9" spread="40.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Who Continued on Study Medication to Month 6</title>
        <description>Retention rate: percent of participants who continued on study medication throughout the 6 Month period after inclusion in the study.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants Who Continued on Study Medication to Month 6</title>
            <description>Retention rate: percent of participants who continued on study medication throughout the 6 Month period after inclusion in the study.</description>
            <units>percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="97.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discontinuation Due to Lack of Efficacy</title>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. As no participants discontinued due to lack of efficacy, the time to exit analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Discontinuation Due to Lack of Efficacy</title>
            <units>days</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discontinuation Due to Safety, Tolerability, or Treatment Compliance</title>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. Due to the low number of participants who discontinued due to safety, tolerability or compliance with treatment, the time to exit analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Discontinuation Due to Safety, Tolerability, or Treatment Compliance</title>
            <units>days</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discontinuation Due to Other Reasons</title>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. Due to the low number of participants who discontinued due to other reasons, the time to exit analyses was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Discontinuation Due to Other Reasons</title>
            <units>days</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Satisfaction Evaluated by Patient Global Impression of Change Visual Analog Scale (VAS)</title>
        <description>Patient Global Impression of Change VAS: subject rated instrument to measure subject's change in overall status; range from 0 (much better) to 10 (much worse).</description>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. The scale for this endpoint was not collected and results were not analyzed as planned.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Treatment Satisfaction Evaluated by Patient Global Impression of Change Visual Analog Scale (VAS)</title>
            <description>Patient Global Impression of Change VAS: subject rated instrument to measure subject's change in overall status; range from 0 (much better) to 10 (much worse).</description>
            <units>scores on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Reaching Monotherapy</title>
        <description>Percent of participants who started on more than one treatment (bitherapy) and reached monotherapy by end of study.</description>
        <time_frame>Baseline through Month 6 (or end of study)</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. N=number of participants who started on bitherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants Reaching Monotherapy</title>
            <description>Percent of participants who started on more than one treatment (bitherapy) and reached monotherapy by end of study.</description>
            <units>percent of partipants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.9" lower_limit="0.6" upper_limit="8.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants That Reduced, Maintained and Increased Their Doses of New Antiepileptic Drugs (AED)</title>
        <time_frame>Baseline to Month 6 (or end of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants That Reduced, Maintained and Increased Their Doses of New Antiepileptic Drugs (AED)</title>
            <units>percent of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Reduced</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" lower_limit="0.0" upper_limit="5.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Maintained</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68.5" lower_limit="58.9" upper_limit="77.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.6" lower_limit="22.1" upper_limit="40.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants That Reduced, Maintained and Increased the Doses of the Initial Treatment Administered in Monotherapy</title>
        <time_frame>Baseline through Month 6 (or end of treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. N= number of subjects with initial treatment administered as monotherapy.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants That Reduced, Maintained and Increased the Doses of the Initial Treatment Administered in Monotherapy</title>
            <units>percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Reduced</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Maintained</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Increased</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in the Hospital Anxiety and Depression Scale (HADS)</title>
        <description>HADS: subject rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. N=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="92"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Month 6 in the Hospital Anxiety and Depression Scale (HADS)</title>
            <description>HADS: subject rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.</description>
            <units>scores on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Depression</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.5" spread="3.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anxiety</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.6" spread="3.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Depression domain: P-value vs baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.1797</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Anxiety domain: P-value vs baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0433</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in Quality of Life 10 Domains (QOLIE-10)</title>
        <description>QOLIE-10: 10-item questionnaire evaluates health-related quality of life in individuals with epliepsy. Comprised of 7 components: seizure worry, overall quality of life, emotional well-being, energy, cognitive functioning, medication effects (physical and mental effects), and social function (work, driving, social function). Total score rated 0 to 100; higher score = higher quality of life.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. N=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Month 6 in Quality of Life 10 Domains (QOLIE-10)</title>
            <description>QOLIE-10: 10-item questionnaire evaluates health-related quality of life in individuals with epliepsy. Comprised of 7 components: seizure worry, overall quality of life, emotional well-being, energy, cognitive functioning, medication effects (physical and mental effects), and social function (work, driving, social function). Total score rated 0 to 100; higher score = higher quality of life.</description>
            <units>scores on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Energy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" spread="17.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Emotions (mood)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.7" spread="16.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Daily activities</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="12.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mental function</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="20.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Medication effects (physical/ mental)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.1" spread="14.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Worry about seizures (impact of seizures)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.0" spread="21.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall quality of life</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.8" spread="17.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Energy: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.8284</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Emotions (mood): p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6299</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Daily activities: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.6162</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Mental function: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5609</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Medication effects (physical/ mental): p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4635</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Worry about seizures (impact of seizures): p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Overall quality of life: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0258</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Months 3 and 6 in Health Condition: Euro Quality of Life Scale (EQ-5D) Visual Analog Scale (VAS)</title>
        <description>Assessment of the health condition of the subjects using the EQ-5D VAS: subject rated questionnaire to assess health-related quality of life in terms of a single index value. Using the VAS subjects rated current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.</description>
        <time_frame>Baseline, Month 3, Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS LOCF. N=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Months 3 and 6 in Health Condition: Euro Quality of Life Scale (EQ-5D) Visual Analog Scale (VAS)</title>
            <description>Assessment of the health condition of the subjects using the EQ-5D VAS: subject rated questionnaire to assess health-related quality of life in terms of a single index value. Using the VAS subjects rated current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.</description>
            <units>scores on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Month 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" spread="16.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="15.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 3: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.7822</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 6: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4471</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sleep Disturbances From Baseline to Month 6: Medical Outcomes Study Sleep Scale (MOS-SS)</title>
        <description>Subject rated instrument to assess key constructs of sleep; assesses sleep quality and quantity. Consists of a 6-item and 9-item overall sleep problems index measuring time to fall asleep and sleep duration in past 4 weeks; 5 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy. Transformed scores range = 0 to 100; higher score indicates greater intensity of attribute. Two additional subscales = sleep quantity (range 0-24 hours) and optimal sleep (number of participants with optimal sleep 7-8 hours per night).</description>
        <time_frame>Baseline to Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS LOCF. Change from baseline in Optimal sleep is not shown as changes from baseline were only evaluated for continuous parameters. N=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="107"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Sleep Disturbances From Baseline to Month 6: Medical Outcomes Study Sleep Scale (MOS-SS)</title>
            <description>Subject rated instrument to assess key constructs of sleep; assesses sleep quality and quantity. Consists of a 6-item and 9-item overall sleep problems index measuring time to fall asleep and sleep duration in past 4 weeks; 5 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy. Transformed scores range = 0 to 100; higher score indicates greater intensity of attribute. Two additional subscales = sleep quantity (range 0-24 hours) and optimal sleep (number of participants with optimal sleep 7-8 hours per night).</description>
            <units>scores on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Sleep disturbance</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.7" spread="15.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Snoring</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" spread="15.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Awake short of breath</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" spread="14.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Quantity</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.2" spread="0.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Adequacy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.8" spread="15.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Somnolence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="11.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep problems (summary 6)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.9" spread="11.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleep problems (summary 9)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.9" spread="13.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Sleep disturbance: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.2452</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Snoring: p-value verus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>1.0000</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Awake short of breath: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4253</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Quantity: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0572</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Adequacy: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0625</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Somnolence: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.5540</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Sleep problems (summary 6): p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4204</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Sleep problems (summary 9): p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.4869</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Indicating Optimal Sleep on the Optimal Sleep Subscale: Medical Outcomes Study Sleep Scale (MOS-SS)</title>
        <description>MOS-SS: subject rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Optimal sleep subscale is derived from sleep quantity average hours of sleep over the past 4 weeks; percent of participants with response YES (optimal) if sleep quantilty was 7-8 hours of sleep per night.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants Indicating Optimal Sleep on the Optimal Sleep Subscale: Medical Outcomes Study Sleep Scale (MOS-SS)</title>
            <description>MOS-SS: subject rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Optimal sleep subscale is derived from sleep quantity average hours of sleep over the past 4 weeks; percent of participants with response YES (optimal) if sleep quantilty was 7-8 hours of sleep per night.</description>
            <units>percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Month 6: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0863</p_value>
            <method>McNemar</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in Visits to a Specialist or the Emergency Room Because of Epilepsy</title>
        <description>Numerical assessment of change in the number of visits to a specialist or the emergency room because of epilepsy needed during the study.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. Costs involved in health and non-health resources needed during the study were not analyzed as planned with this endpoint. N=number of subjects with visits to a specialist because of epilepsy.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Month 6 in Visits to a Specialist or the Emergency Room Because of Epilepsy</title>
            <description>Numerical assessment of change in the number of visits to a specialist or the emergency room because of epilepsy needed during the study.</description>
            <units>visits</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Number of visits to a specialist (n=94)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.6" spread="2.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Number of visits to the emergency room (n=79)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.3" spread="0.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Number of visits to a specialist because of epilepsy: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0226</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Number of visits to the emergency room because of epilepsy: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0017</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 6 in Total Number of Days Hospitalized Because of Epilepsy</title>
        <description>Numerical assessment of change in total number of days hospitalized because of epilepsy during the study.</description>
        <time_frame>Baseline to Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF. N=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Month 6 in Total Number of Days Hospitalized Because of Epilepsy</title>
            <description>Numerical assessment of change in total number of days hospitalized because of epilepsy during the study.</description>
            <units>Days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-8.0" spread="68.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>P-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.3141</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Cessation of Occupation, Requirement of Caregiver, or Admission to Intensive Care Unit</title>
        <description>Percent of participants with cessation of usual occupation, requirement of an informal caregiver, and who required admission to the intensive care unit (ICU).</description>
        <time_frame>Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; LOCF.</population>
        <group_list>
          <group group_id="O1">
            <title>All Antiepileptic Drugs</title>
            <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin: treatment, dose and frequency of administration determined by daily clinical practice</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="108"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants With Cessation of Occupation, Requirement of Caregiver, or Admission to Intensive Care Unit</title>
            <description>Percent of participants with cessation of usual occupation, requirement of an informal caregiver, and who required admission to the intensive care unit (ICU).</description>
            <units>percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Stopped Usual Occupation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Required Informal Caregiver</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Required Admission to ICU</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Cessation of usual occupation: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0708</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Requirement of informal caregiver: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>1.0000</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Required admission to ICU: p-value versus baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>1.0000</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Includes data from baseline to 7 days after last dose of study drug.</time_frame>
      <desc>Safety Population: subjects known to have taken at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Antiepileptic Drugs (Including Pregabalin)</title>
          <description>Pregabalin, Levetiracetam, Topiramate, Lamotrigine, Oxcarbazepine, Zonisamide, Gabapentin</description>
        </group>
        <group group_id="E2">
          <title>Pregabalin (Pregabalin Only)</title>
        </group>
      </group_list>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was cancelled with 111 patients enrolled due to lack of recruitment, and inability to analyze the study by treatment groups. Seizures were analyzed by 3 month data instead of 2 month data as originally planned.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
